Triamcinolone monotherapy loses favor as potential AMD treatment

Article

In the new treatment era for exudative age-related macular degeneration (AMD) heralded by the availability of locally administered anti-VEGF drugs, intravitreal monotherapy with triamcinolone injection may no longer be considered as a current therapy for this neovascular condition, said Jost Jonas, MD, at the World Ophthalmology Congress.

In the new treatment era for exudative age-related macular degeneration (AMD) heralded by the availability of locally administered anti-VEGF drugs, intravitreal monotherapy with triamcinolone injection may no longer be considered as a current therapy for this neovascular condition, said Jost Jonas, MD, at the World Ophthalmology Congress.

Dr. Jonas of the University of Heidelberg, Germany, reviewed the results of studies investigating the efficacy and safety of intravitreal triamcinolone that demonstrated the treatment resulted in benefits in some patients, but also afforded no positive effect for an appreciable proportion, while being associated with high rates of adverse events.

Intraocular pressure (IOP) elevation, occurring in about 40% of eyes, and IOP has risen to frighteningly high levels in some cases. In addition, about 15% to 20% of the older population treated required cataract surgery within 1 year of receiving intravitreal triamcinolone and while serious complications, such as infectious endophthalmitis, have been rare, they did occur and the cumulative rate would be expected to increase with repeated injections.

"Intravitreal triamcinolone may still be a treatment option for a number of intraocular edemas, proliferative, and neovascular diseases, but exudative AMD probably no longer belongs on that list. For AMD, intravitreal triamcinolone may still be used in combination with verteporfin (Visudyne) photodynamic therapy (PDT). However, it remains to be seen whether intravitreal triamcinolone plus PDT may be replaced by anti-VEGF therapy plus PDT or triple therapy with intravitreal triamcinolone plus anti-VEGF therapy plus PDT," said Dr. Jonas.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Related Content
© 2025 MJH Life Sciences

All rights reserved.